Elrig

APRIL 7, 2025

ELRIG Appoints Dr Del Trezise as Chair ELRIG Appoints Dr Del Trezise as Chair New leadership to drive continued growth and collaboration in drug discovery Cambridge, UK, 08 April 2025: ELRIG, a not-for-profit, volunteer-led organisation dedicated to the drug discovery community, has appointed Dr Del Trezise as Chair of the Board.

Assay Development 59

Assay Development Laboratories Science Drugs 59

Sygnature Discovery

JANUARY 17, 2023

Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications.

Compound Screening 52

Compound Screening Marketing Assay Development Drugs 52

Drug Target Review

NOVEMBER 1, 2023

Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. 2013) 56, 2059-2073.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Broad Institute

JUNE 30, 2023

LipocyteProfiler builds on the concept of image-based profiling that was first introduced in the context of morphology mapping by Cell Painting, a high-content imaging assay developed by Broad institute scientist and Imaging Platform senior director Anne Carpenter.

Small Molecule 105

Small Molecule Cell Based Assays Disease Assay Development 105

Sygnature Discovery

JUNE 17, 2024

At Sygnature Discovery, we see biophysics as a core component of drug discovery projects, which can generate data throughout the pipeline. Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities.

Biophysical Assays 52

Biophysical Assays Screening Hits Assay Development Fragment Screening 52

Broad Institute

OCTOBER 17, 2023

Computationally guided high-throughput design of self-assembling drug nanoparticles. He utilized industry-leading laboratory technology to design robust, repeatable experiments, including assay development, training, large screens, and follow-up assays. Nat Chem Biol. 2016;12(2):109-116. doi:10.1038/nchembio.1986

Assay Development 52

Assay Development Laboratories Engineering Science 52

Elrig

APRIL 29, 2024

Webinar | Ai At The Frontier: Empowering Early Career Professionals In Drug Discovery WEBINAR – ARE YOU CURIOUS ABOUT THE CUTTING-EDGE INTERSECTION OF ARTIFICIAL INTELLIGENCE AND DRUG DISCOVERY? Are you curious about the cutting-edge intersection of Artificial Intelligence and Drug Discovery?

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Sygnature Discovery

SEPTEMBER 14, 2023

Sygnature Discovery is delighted to announce that its customer, River BioMedics , has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research. The two companies have collaborated in cardiovascular drug discovery since March 2021.

Small Molecule 52

Small Molecule Assay Development Disease Drug Research 52

PerkinElmer

NOVEMBER 12, 2020

In drug development, assays are test systems that gauge the effects of chemical compounds on certain cellular, molecular, or biochemical processes. They are a vital step in modern pharma research that pushes drugs to market faster. These are just three of the steps to take toward reliable and replicable assay development.

Assay Development 52

Assay Development Drug Development Research Drugs 52

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. Similar to the OTAT town hall meeting in September, potency assay requirements and pitfalls were discussed.

Therapies 59

Therapies Engineering Production FDA 59

Alta Sciences

AUGUST 21, 2023

Efficient Characterization of ADME A critical feature of the bioanalytical platform selected for a drug development program is how well it characterizes the ADME (absorption, distribution, metabolism, excretion) of your molecule of interest. Why Partner With Altasciences for Your Bioanalytical Projects?

Assay Development 52

Assay Development Pharmacokinetics Drug Development Drugs 52

Drug Target Review

OCTOBER 3, 2024

Since the 1970s, when hybridoma technology enabling the generation of monoclonal antibodies (mAbs) was first developed, 1 antibody-based therapeutics have become one of the most rapidly growing drug categories, with applications across cancer indications, immune disorders and infections.

Molecular Biology 52

Molecular Biology Pharmacokinetics Laboratories Animal Testing 52

The Pharma Data

JANUARY 27, 2021

(“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for TD-0148A’s U.S.

FDA 52

FDA Synthetic Chemistry Assay Development Treatment 52

The Premier Consulting Blog

OCTOBER 26, 2022

Definition of the manufacturing process description The Parenteral Drug Association defines the MPD as: A tool used to assist in execution of risk assessments, in the development of the Control Strategy, and for transfer of the process for commercial manufacturing.

Production 40

Production Assay Development Clinical Supply Clinical Development 40

Sygnature Discovery

FEBRUARY 11, 2022

We’re thrilled to be working with cutting-edge new Dutch biotech company River BioMedics to identify new drugs that directly treat heart failure and cardiovascular disease – the number one cause of death in the world. River BioMedics is progressing its cardiovascular disease programmes following a €1.8m

Assay Development 52

Assay Development Disease Engineering Science 52

Agency IQ

FEBRUARY 2, 2024

The EMA started providing guidance on the clinical development of anticancer therapeutics in 1996. The document has been updated over time to implement advances in understanding cancer and drug development. In 2005, the guidance was updated to include non-cytotoxic drugs were gaining in importance.

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40

Agency IQ

JULY 21, 2023

BY RACHEL COE, MSC JUL 18, 2023 11:14 PM CDT Oncology endpoints: The growing pains of an evolving field FDA approval of a drug or biologic relies on whether there is “substantial evidence” of safety and effectiveness derived from “adequate and well-controlled clinical investigations” according to the Federal Food, Drug, and Cosmetic (FD&C) Act.

FDA 40

FDA Clinical Trials Treatment Trials 40

Conversations in Drug Development Trends

JANUARY 6, 2025

Tom Zhang, PhD, Chief Scientific Officer, Large Molecule Bioanalysis Revolutionizing Therapeutic Development with Cutting-Edge Bioanalysis Automation Cutting-edge advancements in bioanalysis (BioA) and drug R&D are reshaping the future of preventative and interventional care, but how do we harness these to their fullest potential?

Clinical Trials 52

Clinical Trials Trials Drug Development Therapies 52

sptlabtech

APRIL 23, 2025

Since 2003, mosquito has been a trusted solution in drug discovery, used by hundreds of pharmaceutical, biotech, and academic labs worldwide. A testament to mosquitos impact in drug discovery is Viral Patel, an expert in molecular pharmacology and a longstanding mosquito user.

Drugs 59

Drugs Compound Screening Laboratories Assay Development 59